2025-02-17 00:00:00
: Portfolio change date
No Asset in the portfolio
The percentage of cash held in the portfolio is:
100%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
CARA |
Buy
All
|
-7.44% |
RGNX |
Sell
All
|
-9.54% |
Assets Rebalanced
None
2025-02-14 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
RGNX
REGENXBIO Inc.
|
Buy |
7.06% |
-9.29% |
2025-02-03 |
CARA
Cara Therapeutics, Inc.
|
Sell |
-5.35% |
-15.7% |
2025-02-03 |
The percentage of cash held in the portfolio is:
98.29%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
FATE |
Sell
All
|
-7.3% |
SGMO |
Sell
All
|
-4.88% |
NTRA |
Sell
All
|
-3.14% |
Assets Rebalanced
None
2025-02-13 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
FATE
Fate Therapeutics, Inc.
|
Buy |
7.45% |
-8.76% |
2025-01-31 |
SGMO
Sangamo Therapeutics, Inc.
|
Buy |
7.5% |
-8.13% |
2025-01-31 |
NTRA
Natera, Inc.
|
Buy |
7.97% |
-2.45% |
2025-01-31 |
RGNX
REGENXBIO Inc.
|
Buy |
6.95% |
-10.78% |
2025-02-03 |
CARA
Cara Therapeutics, Inc.
|
Sell |
-5.02% |
-8.47% |
2025-02-03 |
The percentage of cash held in the portfolio is:
75.15%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
UTMD |
Buy
All
|
1.26% |
AADI |
Buy
All
|
7.27% |
RCKT |
Buy
All
|
5.28% |
Assets Rebalanced
None
2025-02-10 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
FATE
Fate Therapeutics, Inc.
|
Buy |
7.48% |
-7.3% |
2025-01-31 |
SGMO
Sangamo Therapeutics, Inc.
|
Buy |
7.54% |
-6.5% |
2025-01-31 |
NTRA
Natera, Inc.
|
Buy |
7.91% |
-1.96% |
2025-01-31 |
RGNX
REGENXBIO Inc.
|
Buy |
7.83% |
1.73% |
2025-02-03 |
UTMD
Utah Medical Products, Inc.
|
Sell |
-3.83% |
2.37% |
2025-01-30 |
AADI
Aadi Bioscience, Inc.
|
Sell |
-3.76% |
4.15% |
2025-01-30 |
RCKT
Rocket Pharmaceuticals, Inc.
|
Sell |
-3.9% |
0.67% |
2025-01-30 |
CARA
Cara Therapeutics, Inc.
|
Sell |
-4.72% |
-3.31% |
2025-02-03 |
The percentage of cash held in the portfolio is:
85.46%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
BLFS |
Sell
All
|
-7.77% |
Assets Rebalanced
None
2025-02-07 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
BLFS
BioLife Solutions, Inc.
|
Buy |
7.32% |
-7.46% |
2025-01-30 |
FATE
Fate Therapeutics, Inc.
|
Buy |
8.11% |
2.19% |
2025-01-31 |
SGMO
Sangamo Therapeutics, Inc.
|
Buy |
8.2% |
3.25% |
2025-01-31 |
NTRA
Natera, Inc.
|
Buy |
7.89% |
-0.64% |
2025-01-31 |
RGNX
REGENXBIO Inc.
|
Buy |
7.91% |
4.46% |
2025-02-03 |
UTMD
Utah Medical Products, Inc.
|
Sell |
-3.77% |
2.3% |
2025-01-30 |
AADI
Aadi Bioscience, Inc.
|
Sell |
-3.78% |
2.08% |
2025-01-30 |
RCKT
Rocket Pharmaceuticals, Inc.
|
Sell |
-3.95% |
-2.31% |
2025-01-30 |
CARA
Cara Therapeutics, Inc.
|
Sell |
-4.76% |
-5.79% |
2025-02-03 |
The percentage of cash held in the portfolio is:
76.84%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
HROW |
Buy
All
|
7.62% |
Assets Rebalanced
None
2025-02-06 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
BLFS
BioLife Solutions, Inc.
|
Buy |
7.46% |
-5.58% |
2025-01-30 |
FATE
Fate Therapeutics, Inc.
|
Buy |
8.23% |
3.65% |
2025-01-31 |
SGMO
Sangamo Therapeutics, Inc.
|
Buy |
8.13% |
2.44% |
2025-01-31 |
NTRA
Natera, Inc.
|
Buy |
7.97% |
0.41% |
2025-01-31 |
RGNX
REGENXBIO Inc.
|
Buy |
7.91% |
4.46% |
2025-02-03 |
HROW
Harrow Health, Inc.
|
Sell |
-3.67% |
8.07% |
2025-01-24 |
UTMD
Utah Medical Products, Inc.
|
Sell |
-3.78% |
2.14% |
2025-01-30 |
AADI
Aadi Bioscience, Inc.
|
Sell |
-3.87% |
-0.35% |
2025-01-30 |
RCKT
Rocket Pharmaceuticals, Inc.
|
Sell |
-4.17% |
-7.97% |
2025-01-30 |
CARA
Cara Therapeutics, Inc.
|
Sell |
-4.68% |
-4.13% |
2025-02-03 |
The percentage of cash held in the portfolio is:
80.48%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
FGEN |
Buy
All
|
-0.6% |
Assets Rebalanced
None
2025-02-05 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
BLFS
BioLife Solutions, Inc.
|
Buy |
7.37% |
-6.96% |
2025-01-30 |
FATE
Fate Therapeutics, Inc.
|
Buy |
7.61% |
-4.38% |
2025-01-31 |
SGMO
Sangamo Therapeutics, Inc.
|
Buy |
8.02% |
0.81% |
2025-01-31 |
NTRA
Natera, Inc.
|
Buy |
7.86% |
-1.15% |
2025-01-31 |
RGNX
REGENXBIO Inc.
|
Buy |
7.93% |
4.46% |
2025-02-03 |
FGEN
FibroGen, Inc.
|
Sell |
-3.52% |
8.1% |
2025-01-23 |
HROW
Harrow Health, Inc.
|
Sell |
-3.68% |
8.24% |
2025-01-24 |
UTMD
Utah Medical Products, Inc.
|
Sell |
-3.79% |
2.17% |
2025-01-30 |
AADI
Aadi Bioscience, Inc.
|
Sell |
-3.66% |
5.54% |
2025-01-30 |
RCKT
Rocket Pharmaceuticals, Inc.
|
Sell |
-4.12% |
-6.44% |
2025-01-30 |
CARA
Cara Therapeutics, Inc.
|
Sell |
-4.57% |
-1.45% |
2025-02-03 |
The percentage of cash held in the portfolio is:
84.54%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
TNDM |
Buy
All
|
-1.95% |
MDRX |
Buy
All
|
47.11% |
BHVN |
Sell
All
|
0.72% |
AGEN |
Sell
All
|
-8.62% |
Assets Rebalanced
None
2025-02-04 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
BHVN
Biohaven Ltd.
|
Buy |
5.52% |
-3.38% |
2025-01-22 |
AGEN
Agenus Inc.
|
Buy |
5.24% |
-8.36% |
2025-01-22 |
BLFS
BioLife Solutions, Inc.
|
Buy |
7.54% |
-5.94% |
2025-01-30 |
FATE
Fate Therapeutics, Inc.
|
Buy |
7.46% |
-7.3% |
2025-01-31 |
SGMO
Sangamo Therapeutics, Inc.
|
Buy |
7.65% |
-4.88% |
2025-01-31 |
NTRA
Natera, Inc.
|
Buy |
8.06% |
0.16% |
2025-01-31 |
RGNX
REGENXBIO Inc.
|
Buy |
7.44% |
-3.1% |
2025-02-03 |
TNDM
Tandem Diabetes Care, Inc.
|
Sell |
-4.03% |
-3.12% |
2025-01-22 |
MDRX
Allscripts Healthcare Solutions, Inc.
|
Sell |
-2.17% |
44.44% |
2025-01-22 |
FGEN
FibroGen, Inc.
|
Sell |
-3.66% |
5.56% |
2025-01-23 |
HROW
Harrow Health, Inc.
|
Sell |
-3.6% |
11.22% |
2025-01-24 |
UTMD
Utah Medical Products, Inc.
|
Sell |
-3.83% |
2.27% |
2025-01-30 |
AADI
Aadi Bioscience, Inc.
|
Sell |
-3.71% |
5.19% |
2025-01-30 |
RCKT
Rocket Pharmaceuticals, Inc.
|
Sell |
-3.97% |
-1.44% |
2025-01-30 |
CARA
Cara Therapeutics, Inc.
|
Sell |
-4.5% |
1.24% |
2025-02-03 |
The percentage of cash held in the portfolio is:
80.56%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
SIGA |
Sell
All
|
-9.55% |
Assets Rebalanced
None
2025-02-03 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
BHVN
Biohaven Ltd.
|
Buy |
5.54% |
-2% |
2025-01-22 |
AGEN
Agenus Inc.
|
Buy |
5.61% |
-0.78% |
2025-01-22 |
SIGA
SIGA Technologies, Inc.
|
Buy |
9.71% |
-6.42% |
2025-01-23 |
BLFS
BioLife Solutions, Inc.
|
Buy |
7.66% |
-3.5% |
2025-01-30 |
FATE
Fate Therapeutics, Inc.
|
Buy |
7.56% |
-5.11% |
2025-01-31 |
SGMO
Sangamo Therapeutics, Inc.
|
Buy |
7.96% |
0% |
2025-01-31 |
NTRA
Natera, Inc.
|
Buy |
7.99% |
0.37% |
2025-01-31 |
RGNX
REGENXBIO Inc.
|
Buy |
7.6% |
0% |
2025-02-03 |
TNDM
Tandem Diabetes Care, Inc.
|
Sell |
-4.06% |
-4.99% |
2025-01-22 |
MDRX
Allscripts Healthcare Solutions, Inc.
|
Sell |
-2.35% |
39.33% |
2025-01-22 |
FGEN
FibroGen, Inc.
|
Sell |
-3.69% |
3.97% |
2025-01-23 |
HROW
Harrow Health, Inc.
|
Sell |
-3.67% |
8.57% |
2025-01-24 |
UTMD
Utah Medical Products, Inc.
|
Sell |
-3.87% |
0.13% |
2025-01-30 |
AADI
Aadi Bioscience, Inc.
|
Sell |
-3.86% |
0.35% |
2025-01-30 |
RCKT
Rocket Pharmaceuticals, Inc.
|
Sell |
-4% |
-3.17% |
2025-01-30 |
CARA
Cara Therapeutics, Inc.
|
Sell |
-4.51% |
0% |
2025-02-03 |
The percentage of cash held in the portfolio is:
70.37%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
CPRX |
Sell
All
|
-5.84% |
TGTX |
Sell
All
|
-0.69% |
SENS |
Sell
All
|
-14.96% |
Assets Rebalanced
None
2025-01-31 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
BHVN
Biohaven Ltd.
|
Buy |
5.65% |
-0.08% |
2025-01-22 |
AGEN
Agenus Inc.
|
Buy |
5.23% |
-7.57% |
2025-01-22 |
SIGA
SIGA Technologies, Inc.
|
Buy |
9.99% |
-3.6% |
2025-01-23 |
SENS
Senseonics Holdings, Inc.
|
Buy |
3.29% |
-3.54% |
2025-01-27 |
TGTX
TG Therapeutics, Inc.
|
Buy |
5.61% |
4.51% |
2025-01-28 |
BLFS
BioLife Solutions, Inc.
|
Buy |
7.76% |
-2.12% |
2025-01-30 |
CPRX
Catalyst Pharmaceuticals, Inc.
|
Buy |
7.68% |
-3.21% |
2025-01-30 |
FATE
Fate Therapeutics, Inc.
|
Buy |
7.96% |
0% |
2025-01-31 |
SGMO
Sangamo Therapeutics, Inc.
|
Buy |
7.96% |
0% |
2025-01-31 |
NTRA
Natera, Inc.
|
Buy |
7.96% |
0% |
2025-01-31 |
TNDM
Tandem Diabetes Care, Inc.
|
Sell |
-4.05% |
-4.84% |
2025-01-22 |
MDRX
Allscripts Healthcare Solutions, Inc.
|
Sell |
-3.43% |
11.11% |
2025-01-22 |
FGEN
FibroGen, Inc.
|
Sell |
-3.83% |
0.28% |
2025-01-23 |
HROW
Harrow Health, Inc.
|
Sell |
-3.78% |
5.68% |
2025-01-24 |
UTMD
Utah Medical Products, Inc.
|
Sell |
-3.87% |
0.15% |
2025-01-30 |
AADI
Aadi Bioscience, Inc.
|
Sell |
-3.86% |
0.35% |
2025-01-30 |
RCKT
Rocket Pharmaceuticals, Inc.
|
Sell |
-3.98% |
-2.69% |
2025-01-30 |
The percentage of cash held in the portfolio is:
57.72%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
ORGO |
Sell
All
|
13.21% |
Assets Rebalanced
None
2025-01-30 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
ORGO
Organogenesis Holdings Inc.
|
Buy |
8.2% |
14.11% |
2025-01-17 |
BHVN
Biohaven Ltd.
|
Buy |
5.42% |
-3.33% |
2025-01-22 |
AGEN
Agenus Inc.
|
Buy |
5.28% |
-5.74% |
2025-01-22 |
SIGA
SIGA Technologies, Inc.
|
Buy |
10.07% |
-2.03% |
2025-01-23 |
SENS
Senseonics Holdings, Inc.
|
Buy |
3.11% |
-7.96% |
2025-01-27 |
TGTX
TG Therapeutics, Inc.
|
Buy |
5.56% |
4.54% |
2025-01-28 |
BLFS
BioLife Solutions, Inc.
|
Buy |
7.86% |
0% |
2025-01-30 |
CPRX
Catalyst Pharmaceuticals, Inc.
|
Buy |
7.86% |
0% |
2025-01-30 |
TNDM
Tandem Diabetes Care, Inc.
|
Sell |
-3.95% |
-3% |
2025-01-22 |
MDRX
Allscripts Healthcare Solutions, Inc.
|
Sell |
-3.24% |
15.44% |
2025-01-22 |
FGEN
FibroGen, Inc.
|
Sell |
-3.62% |
4.76% |
2025-01-23 |
HROW
Harrow Health, Inc.
|
Sell |
-3.83% |
3.72% |
2025-01-24 |
UTMD
Utah Medical Products, Inc.
|
Sell |
-3.84% |
0% |
2025-01-30 |
AADI
Aadi Bioscience, Inc.
|
Sell |
-3.84% |
0% |
2025-01-30 |
RCKT
Rocket Pharmaceuticals, Inc.
|
Sell |
-3.84% |
0% |
2025-01-30 |
The percentage of cash held in the portfolio is:
72.78%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
MDXG |
Sell
All
|
2.61% |
CERS |
Sell
All
|
4.86% |
ATXS |
Sell
All
|
-4.24% |
NVRO |
Sell
All
|
19.34% |
AXSM |
Sell
All
|
12.15% |
DNLI |
Sell
All
|
8.88% |
MD |
Sell
All
|
1.36% |
LGND |
Sell
All
|
7.83% |
Assets Rebalanced
None
2025-01-29 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
MDXG
MiMedx Group, Inc.
|
Buy |
7.69% |
2.72% |
2025-01-16 |
CERS
Cerus Corporation
|
Buy |
8.58% |
14.59% |
2025-01-16 |
ATXS
Astria Therapeutics, Inc.
|
Buy |
7.2% |
-3.85% |
2025-01-16 |
NVRO
Nevro Corp.
|
Buy |
7.12% |
17.69% |
2025-01-16 |
AXSM
Axsome Therapeutics, Inc.
|
Buy |
7% |
9.29% |
2025-01-16 |
DNLI
Denali Therapeutics Inc.
|
Buy |
7.04% |
9.3% |
2025-01-16 |
MD
Pediatrix Medical Group, Inc.
|
Buy |
7.85% |
3.29% |
2025-01-16 |
LGND
Ligand Pharmaceuticals Incorporated
|
Buy |
7.44% |
7.1% |
2025-01-16 |
ORGO
Organogenesis Holdings Inc.
|
Buy |
7.69% |
6.91% |
2025-01-17 |
BHVN
Biohaven Ltd.
|
Buy |
5.52% |
-1.69% |
2025-01-22 |
AGEN
Agenus Inc.
|
Buy |
5.21% |
-7.05% |
2025-01-22 |
SIGA
SIGA Technologies, Inc.
|
Buy |
9.98% |
-2.97% |
2025-01-23 |
SENS
Senseonics Holdings, Inc.
|
Buy |
3.33% |
-1.77% |
2025-01-27 |
TGTX
TG Therapeutics, Inc.
|
Buy |
5.58% |
4.79% |
2025-01-28 |
TNDM
Tandem Diabetes Care, Inc.
|
Sell |
-3.95% |
-3.12% |
2025-01-22 |
MDRX
Allscripts Healthcare Solutions, Inc.
|
Sell |
-3.41% |
11.11% |
2025-01-22 |
FGEN
FibroGen, Inc.
|
Sell |
-3.7% |
2.78% |
2025-01-23 |
HROW
Harrow Health, Inc.
|
Sell |
-3.87% |
2.68% |
2025-01-24 |
The percentage of cash held in the portfolio is:
17.72%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
GERN |
Buy
All
|
-2.04% |
NUTX |
Sell
All
|
33.72% |
ACRS |
Sell
All
|
-4.4% |
Assets Rebalanced
None
2025-01-28 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
NUTX
Nutex Health Inc.
|
Buy |
7.39% |
26.44% |
2025-01-15 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
6.56% |
-2% |
2025-01-15 |
MDXG
MiMedx Group, Inc.
|
Buy |
7.36% |
-1.25% |
2025-01-16 |
CERS
Cerus Corporation
|
Buy |
8.66% |
16.22% |
2025-01-16 |
ATXS
Astria Therapeutics, Inc.
|
Buy |
7.21% |
-3.21% |
2025-01-16 |
NVRO
Nevro Corp.
|
Buy |
7.11% |
18.16% |
2025-01-16 |
AXSM
Axsome Therapeutics, Inc.
|
Buy |
6.99% |
9.54% |
2025-01-16 |
DNLI
Denali Therapeutics Inc.
|
Buy |
6.92% |
7.86% |
2025-01-16 |
MD
Pediatrix Medical Group, Inc.
|
Buy |
7.94% |
4.86% |
2025-01-16 |
LGND
Ligand Pharmaceuticals Incorporated
|
Buy |
7.36% |
6.35% |
2025-01-16 |
ORGO
Organogenesis Holdings Inc.
|
Buy |
8.05% |
12.31% |
2025-01-17 |
BHVN
Biohaven Ltd.
|
Buy |
5.72% |
2.31% |
2025-01-22 |
AGEN
Agenus Inc.
|
Buy |
5.25% |
-6.01% |
2025-01-22 |
SIGA
SIGA Technologies, Inc.
|
Buy |
10.16% |
-0.78% |
2025-01-23 |
SENS
Senseonics Holdings, Inc.
|
Buy |
3.16% |
-6.19% |
2025-01-27 |
TGTX
TG Therapeutics, Inc.
|
Buy |
5.3% |
0% |
2025-01-28 |
GERN
Geron Corporation
|
Sell |
-3.82% |
-0.68% |
2025-01-15 |
TNDM
Tandem Diabetes Care, Inc.
|
Sell |
-3.96% |
-3.6% |
2025-01-22 |
MDRX
Allscripts Healthcare Solutions, Inc.
|
Sell |
-3.19% |
16.33% |
2025-01-22 |
FGEN
FibroGen, Inc.
|
Sell |
-3.67% |
3.17% |
2025-01-23 |
HROW
Harrow Health, Inc.
|
Sell |
-3.81% |
3.9% |
2025-01-24 |
The percentage of cash held in the portfolio is:
7.3%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
AVXL |
Buy
All
|
6.92% |
INSM |
Sell
All
|
12.62% |
AXGN |
Sell
All
|
-1.75% |
Assets Rebalanced
None
2025-01-27 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
INSM
Insmed Incorporated
|
Buy |
7.92% |
13.85% |
2025-01-14 |
AXGN
AxoGen, Inc.
|
Buy |
6.77% |
-0.6% |
2025-01-14 |
NUTX
Nutex Health Inc.
|
Buy |
7.87% |
32.94% |
2025-01-15 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
6.81% |
0.4% |
2025-01-15 |
MDXG
MiMedx Group, Inc.
|
Buy |
7.53% |
-0.34% |
2025-01-16 |
CERS
Cerus Corporation
|
Buy |
8.04% |
6.49% |
2025-01-16 |
ATXS
Astria Therapeutics, Inc.
|
Buy |
7.18% |
-4.88% |
2025-01-16 |
NVRO
Nevro Corp.
|
Buy |
7.42% |
21.7% |
2025-01-16 |
AXSM
Axsome Therapeutics, Inc.
|
Buy |
7.11% |
9.98% |
2025-01-16 |
DNLI
Denali Therapeutics Inc.
|
Buy |
6.72% |
3.35% |
2025-01-16 |
MD
Pediatrix Medical Group, Inc.
|
Buy |
7.85% |
2.29% |
2025-01-16 |
LGND
Ligand Pharmaceuticals Incorporated
|
Buy |
7.31% |
4.31% |
2025-01-16 |
ORGO
Organogenesis Holdings Inc.
|
Buy |
7.76% |
6.91% |
2025-01-17 |
BHVN
Biohaven Ltd.
|
Buy |
5.7% |
0.77% |
2025-01-22 |
AGEN
Agenus Inc.
|
Buy |
5.28% |
-6.79% |
2025-01-22 |
SIGA
SIGA Technologies, Inc.
|
Buy |
10.48% |
0.94% |
2025-01-23 |
SENS
Senseonics Holdings, Inc.
|
Buy |
3.42% |
0% |
2025-01-27 |
AVXL
Anavex Life Sciences Corp.
|
Sell |
-4.01% |
0.57% |
2025-01-14 |
GERN
Geron Corporation
|
Sell |
-3.93% |
-2.38% |
2025-01-15 |
TNDM
Tandem Diabetes Care, Inc.
|
Sell |
-4% |
-3.4% |
2025-01-22 |
MDRX
Allscripts Healthcare Solutions, Inc.
|
Sell |
-3.35% |
13.33% |
2025-01-22 |
FGEN
FibroGen, Inc.
|
Sell |
-3.88% |
-0.99% |
2025-01-23 |
HROW
Harrow Health, Inc.
|
Sell |
-3.99% |
0.68% |
2025-01-24 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
VKTX |
Buy
All
|
12.24% |
ESPR |
Sell
All
|
-10.26% |
Assets Rebalanced
None
2025-01-24 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
6.31% |
-11.11% |
2025-01-13 |
INSM
Insmed Incorporated
|
Buy |
7.81% |
12.93% |
2025-01-14 |
AXGN
AxoGen, Inc.
|
Buy |
6.94% |
2.47% |
2025-01-14 |
NUTX
Nutex Health Inc.
|
Buy |
7.53% |
28% |
2025-01-15 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
6.87% |
2% |
2025-01-15 |
MDXG
MiMedx Group, Inc.
|
Buy |
7.69% |
2.38% |
2025-01-16 |
CERS
Cerus Corporation
|
Buy |
7.51% |
0% |
2025-01-16 |
ATXS
Astria Therapeutics, Inc.
|
Buy |
7.28% |
-3.08% |
2025-01-16 |
NVRO
Nevro Corp.
|
Buy |
7.27% |
19.81% |
2025-01-16 |
AXSM
Axsome Therapeutics, Inc.
|
Buy |
7.12% |
10.82% |
2025-01-16 |
DNLI
Denali Therapeutics Inc.
|
Buy |
7% |
8.28% |
2025-01-16 |
MD
Pediatrix Medical Group, Inc.
|
Buy |
7.71% |
1.14% |
2025-01-16 |
LGND
Ligand Pharmaceuticals Incorporated
|
Buy |
7.29% |
4.62% |
2025-01-16 |
ORGO
Organogenesis Holdings Inc.
|
Buy |
7.65% |
6.01% |
2025-01-17 |
BHVN
Biohaven Ltd.
|
Buy |
5.87% |
4.3% |
2025-01-22 |
AGEN
Agenus Inc.
|
Buy |
5.53% |
-1.83% |
2025-01-22 |
SIGA
SIGA Technologies, Inc.
|
Buy |
10.45% |
1.25% |
2025-01-23 |
VKTX
Viking Therapeutics, Inc.
|
Sell |
-3.21% |
11.12% |
2025-01-13 |
AVXL
Anavex Life Sciences Corp.
|
Sell |
-3.88% |
3.32% |
2025-01-14 |
GERN
Geron Corporation
|
Sell |
-3.92% |
-2.72% |
2025-01-15 |
TNDM
Tandem Diabetes Care, Inc.
|
Sell |
-3.87% |
-0.54% |
2025-01-22 |
MDRX
Allscripts Healthcare Solutions, Inc.
|
Sell |
-3.31% |
13.89% |
2025-01-22 |
FGEN
FibroGen, Inc.
|
Sell |
-3.83% |
-0.4% |
2025-01-23 |
HROW
Harrow Health, Inc.
|
Sell |
-3.99% |
0% |
2025-01-24 |
The percentage of cash held in the portfolio is:
2.18%
New Assets Added
Assets Removed
None
Assets Rebalanced
Asset |
Action |
Weight |
INSM |
Buy |
0.34% |
ORGO |
Buy |
0.41% |
MD |
Buy |
0.8% |
LGND |
Buy |
0.96% |
2025-01-23 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
6.74% |
-5.98% |
2025-01-13 |
AXGN
AxoGen, Inc.
|
Buy |
7.08% |
3.51% |
2025-01-14 |
INSM
Insmed Incorporated
|
Buy |
7.08% |
13.81% |
2025-01-14 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
7.08% |
4% |
2025-01-15 |
NUTX
Nutex Health Inc.
|
Buy |
7.08% |
19.09% |
2025-01-15 |
MDXG
MiMedx Group, Inc.
|
Buy |
7.73% |
1.93% |
2025-01-16 |
CERS
Cerus Corporation
|
Buy |
7.42% |
-2.16% |
2025-01-16 |
ATXS
Astria Therapeutics, Inc.
|
Buy |
7.3% |
-3.72% |
2025-01-16 |
MD
Pediatrix Medical Group, Inc.
|
Buy |
6.51% |
0.5% |
2025-01-16 |
DNLI
Denali Therapeutics Inc.
|
Buy |
7.08% |
8.42% |
2025-01-16 |
AXSM
Axsome Therapeutics, Inc.
|
Buy |
7.08% |
9.09% |
2025-01-16 |
LGND
Ligand Pharmaceuticals Incorporated
|
Buy |
6.43% |
5.06% |
2025-01-16 |
NVRO
Nevro Corp.
|
Buy |
7.08% |
15.57% |
2025-01-16 |
ORGO
Organogenesis Holdings Inc.
|
Buy |
6.89% |
5.11% |
2025-01-17 |
AGEN
Agenus Inc.
|
Buy |
5.43% |
-4.44% |
2025-01-22 |
BHVN
Biohaven Ltd.
|
Buy |
5.9% |
3.92% |
2025-01-22 |
SIGA
SIGA Technologies, Inc.
|
Buy |
10.42% |
0% |
2025-01-23 |
VKTX
Viking Therapeutics, Inc.
|
Sell |
-3.15% |
13.38% |
2025-01-13 |
AVXL
Anavex Life Sciences Corp.
|
Sell |
-3.84% |
5.31% |
2025-01-14 |
GERN
Geron Corporation
|
Sell |
-3.92% |
-1.7% |
2025-01-15 |
TNDM
Tandem Diabetes Care, Inc.
|
Sell |
-3.85% |
0.85% |
2025-01-22 |
MDRX
Allscripts Healthcare Solutions, Inc.
|
Sell |
-3.68% |
5.33% |
2025-01-22 |
FGEN
FibroGen, Inc.
|
Sell |
-3.86% |
0% |
2025-01-23 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
ORMP |
Buy
All
|
2.94% |
EBS |
Buy
All
|
-15.52% |
MCRB |
Buy
All
|
-24.76% |
AORT |
Sell
All
|
1.82% |
Assets Rebalanced
Asset |
Action |
Weight |
MD |
Sell |
-1.1% |
LGND |
Sell |
-1.54% |
AXGN |
Sell |
-1.1% |
DNLI |
Sell |
-1.14% |
ACRS |
Sell |
-1.15% |
AXSM |
Sell |
-1.19% |
NVRO |
Sell |
-1.68% |
INSM |
Sell |
-1.92% |
NUTX |
Sell |
-2.35% |
2025-01-22 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
AORT
Artivion, Inc.
|
Buy |
6.49% |
4.5% |
2025-01-09 |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
6.54% |
-8.12% |
2025-01-13 |
AXGN
AxoGen, Inc.
|
Buy |
8.15% |
3.95% |
2025-01-14 |
INSM
Insmed Incorporated
|
Buy |
8.74% |
11.34% |
2025-01-14 |
NUTX
Nutex Health Inc.
|
Buy |
9.45% |
20.31% |
2025-01-15 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
8.17% |
4% |
2025-01-15 |
MD
Pediatrix Medical Group, Inc.
|
Buy |
7.53% |
0% |
2025-01-16 |
MDXG
MiMedx Group, Inc.
|
Buy |
7.8% |
3.63% |
2025-01-16 |
NVRO
Nevro Corp.
|
Buy |
8.31% |
10.38% |
2025-01-16 |
LGND
Ligand Pharmaceuticals Incorporated
|
Buy |
8.01% |
6.42% |
2025-01-16 |
AXSM
Axsome Therapeutics, Inc.
|
Buy |
7.72% |
2.59% |
2025-01-16 |
CERS
Cerus Corporation
|
Buy |
7.53% |
0% |
2025-01-16 |
DNLI
Denali Therapeutics Inc.
|
Buy |
8.07% |
7.16% |
2025-01-16 |
ATXS
Astria Therapeutics, Inc.
|
Buy |
7.31% |
-2.82% |
2025-01-16 |
ORGO
Organogenesis Holdings Inc.
|
Buy |
6.9% |
6.01% |
2025-01-17 |
AGEN
Agenus Inc.
|
Buy |
5.64% |
0% |
2025-01-22 |
BHVN
Biohaven Ltd.
|
Buy |
5.64% |
0% |
2025-01-22 |
ORMP
Oramed Pharmaceuticals Inc.
|
Sell |
-3.43% |
3.36% |
2025-01-09 |
VKTX
Viking Therapeutics, Inc.
|
Sell |
-3.02% |
16.38% |
2025-01-13 |
AVXL
Anavex Life Sciences Corp.
|
Sell |
-3.76% |
6.64% |
2025-01-14 |
EBS
Emergent BioSolutions Inc.
|
Sell |
-4.37% |
-8.61% |
2025-01-14 |
GERN
Geron Corporation
|
Sell |
-3.85% |
-0.68% |
2025-01-15 |
MDRX
Allscripts Healthcare Solutions, Inc.
|
Sell |
-3.86% |
0% |
2025-01-22 |
TNDM
Tandem Diabetes Care, Inc.
|
Sell |
-3.86% |
0% |
2025-01-22 |
MCRB
Seres Therapeutics, Inc.
|
Sell |
-3.86% |
0% |
2025-01-22 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
FATE |
Buy
All
|
24.57% |
APLS |
Buy
All
|
-9.8% |
Assets Rebalanced
None
2025-01-21 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
AORT
Artivion, Inc.
|
Buy |
6.48% |
1.62% |
2025-01-09 |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
6.9% |
-5.56% |
2025-01-13 |
AXGN
AxoGen, Inc.
|
Buy |
7.98% |
-0.88% |
2025-01-14 |
INSM
Insmed Incorporated
|
Buy |
8.47% |
5.19% |
2025-01-14 |
NUTX
Nutex Health Inc.
|
Buy |
9.52% |
18.16% |
2025-01-15 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
8.29% |
2.8% |
2025-01-15 |
MD
Pediatrix Medical Group, Inc.
|
Buy |
7.64% |
-1.14% |
2025-01-16 |
MDXG
MiMedx Group, Inc.
|
Buy |
7.99% |
3.4% |
2025-01-16 |
NVRO
Nevro Corp.
|
Buy |
8.32% |
7.78% |
2025-01-16 |
LGND
Ligand Pharmaceuticals Incorporated
|
Buy |
7.84% |
1.46% |
2025-01-16 |
AXSM
Axsome Therapeutics, Inc.
|
Buy |
7.57% |
-1.94% |
2025-01-16 |
CERS
Cerus Corporation
|
Buy |
7.47% |
-3.24% |
2025-01-16 |
DNLI
Denali Therapeutics Inc.
|
Buy |
7.88% |
2% |
2025-01-16 |
ATXS
Astria Therapeutics, Inc.
|
Buy |
7.44% |
-3.72% |
2025-01-16 |
ORGO
Organogenesis Holdings Inc.
|
Buy |
6.7% |
0.3% |
2025-01-17 |
FATE
Fate Therapeutics, Inc.
|
Sell |
-2.65% |
27.43% |
2025-01-08 |
ORMP
Oramed Pharmaceuticals Inc.
|
Sell |
-3.49% |
4.2% |
2025-01-09 |
APLS
Apellis Pharmaceuticals, Inc.
|
Sell |
-4.05% |
-9.09% |
2025-01-13 |
VKTX
Viking Therapeutics, Inc.
|
Sell |
-3.08% |
16.94% |
2025-01-13 |
AVXL
Anavex Life Sciences Corp.
|
Sell |
-3.6% |
12.7% |
2025-01-14 |
EBS
Emergent BioSolutions Inc.
|
Sell |
-4.33% |
-4.99% |
2025-01-14 |
GERN
Geron Corporation
|
Sell |
-3.86% |
1.7% |
2025-01-15 |
The percentage of cash held in the portfolio is:
8.59%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
TGTX |
Buy
All
|
NA |
TNDM |
Sell
All
|
NA |
BLUE |
Sell
All
|
NA |
Assets Rebalanced
None
2025-01-17 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
5.88% |
0.47% |
2025-01-07 |
BLUE
bluebird bio, Inc.
|
Buy |
4.87% |
-16.73% |
2025-01-07 |
AORT
Artivion, Inc.
|
Buy |
6.56% |
3.34% |
2025-01-09 |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
7.03% |
-3.42% |
2025-01-13 |
AXGN
AxoGen, Inc.
|
Buy |
8.1% |
0.99% |
2025-01-14 |
INSM
Insmed Incorporated
|
Buy |
8.47% |
5.54% |
2025-01-14 |
NUTX
Nutex Health Inc.
|
Buy |
9.5% |
18.31% |
2025-01-15 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
8.07% |
0.4% |
2025-01-15 |
MD
Pediatrix Medical Group, Inc.
|
Buy |
7.57% |
-1.64% |
2025-01-16 |
MDXG
MiMedx Group, Inc.
|
Buy |
7.92% |
2.95% |
2025-01-16 |
NVRO
Nevro Corp.
|
Buy |
8.17% |
6.13% |
2025-01-16 |
LGND
Ligand Pharmaceuticals Incorporated
|
Buy |
7.75% |
0.73% |
2025-01-16 |
AXSM
Axsome Therapeutics, Inc.
|
Buy |
7.69% |
-0.06% |
2025-01-16 |
CERS
Cerus Corporation
|
Buy |
7.57% |
-1.62% |
2025-01-16 |
DNLI
Denali Therapeutics Inc.
|
Buy |
7.76% |
0.79% |
2025-01-16 |
ATXS
Astria Therapeutics, Inc.
|
Buy |
7.66% |
-0.51% |
2025-01-16 |
ORGO
Organogenesis Holdings Inc.
|
Buy |
6.66% |
0% |
2025-01-17 |
TGTX
TG Therapeutics, Inc.
|
Sell |
-3.81% |
-4.07% |
2025-01-07 |
FATE
Fate Therapeutics, Inc.
|
Sell |
-2.6% |
28.57% |
2025-01-08 |
ORMP
Oramed Pharmaceuticals Inc.
|
Sell |
-3.54% |
2.52% |
2025-01-09 |
APLS
Apellis Pharmaceuticals, Inc.
|
Sell |
-4% |
-8.35% |
2025-01-13 |
VKTX
Viking Therapeutics, Inc.
|
Sell |
-3.06% |
17.17% |
2025-01-13 |
AVXL
Anavex Life Sciences Corp.
|
Sell |
-3.96% |
3.79% |
2025-01-14 |
EBS
Emergent BioSolutions Inc.
|
Sell |
-4.36% |
-5.95% |
2025-01-14 |
GERN
Geron Corporation
|
Sell |
-3.89% |
0.68% |
2025-01-15 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
MDRX |
Sell
All
|
-6.56% |
Assets Rebalanced
None
2025-01-16 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
5.82% |
-3.76% |
2025-01-07 |
BLUE
bluebird bio, Inc.
|
Buy |
5.05% |
-16.43% |
2025-01-07 |
MDRX
Allscripts Healthcare Solutions, Inc.
|
Buy |
6.02% |
-4.51% |
2025-01-08 |
AORT
Artivion, Inc.
|
Buy |
6.53% |
-0.56% |
2025-01-09 |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
7.11% |
-5.56% |
2025-01-13 |
AXGN
AxoGen, Inc.
|
Buy |
8.51% |
2.63% |
2025-01-14 |
INSM
Insmed Incorporated
|
Buy |
8.45% |
1.84% |
2025-01-14 |
NUTX
Nutex Health Inc.
|
Buy |
8.49% |
2.16% |
2025-01-15 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
8.34% |
0.4% |
2025-01-15 |
MD
Pediatrix Medical Group, Inc.
|
Buy |
7.96% |
0% |
2025-01-16 |
MDXG
MiMedx Group, Inc.
|
Buy |
7.96% |
0% |
2025-01-16 |
NVRO
Nevro Corp.
|
Buy |
7.96% |
0% |
2025-01-16 |
LGND
Ligand Pharmaceuticals Incorporated
|
Buy |
7.96% |
0% |
2025-01-16 |
AXSM
Axsome Therapeutics, Inc.
|
Buy |
7.96% |
0% |
2025-01-16 |
CERS
Cerus Corporation
|
Buy |
7.96% |
0% |
2025-01-16 |
DNLI
Denali Therapeutics Inc.
|
Buy |
7.96% |
0% |
2025-01-16 |
ATXS
Astria Therapeutics, Inc.
|
Buy |
7.96% |
0% |
2025-01-16 |
TGTX
TG Therapeutics, Inc.
|
Sell |
-4.08% |
-7.79% |
2025-01-07 |
FATE
Fate Therapeutics, Inc.
|
Sell |
-2.84% |
24.57% |
2025-01-08 |
ORMP
Oramed Pharmaceuticals Inc.
|
Sell |
-3.69% |
1.68% |
2025-01-09 |
APLS
Apellis Pharmaceuticals, Inc.
|
Sell |
-4.04% |
-5.79% |
2025-01-13 |
VKTX
Viking Therapeutics, Inc.
|
Sell |
-3.39% |
11.32% |
2025-01-13 |
AVXL
Anavex Life Sciences Corp.
|
Sell |
-4.57% |
-7.39% |
2025-01-14 |
EBS
Emergent BioSolutions Inc.
|
Sell |
-4.3% |
-1.17% |
2025-01-14 |
GERN
Geron Corporation
|
Sell |
-4.14% |
-2.38% |
2025-01-15 |
The percentage of cash held in the portfolio is:
3.07%
New Assets Added
- MD
- MDXG
- NVRO
- LGND
- AXSM
- CERS
- DNLI
- ATXS
Assets Removed
Asset |
Action |
Perf % |
ARDX |
Sell
All
|
0.19% |
Assets Rebalanced
None
2025-01-15 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
5.78% |
-4.19% |
2025-01-07 |
BLUE
bluebird bio, Inc.
|
Buy |
4.87% |
-19.25% |
2025-01-07 |
MDRX
Allscripts Healthcare Solutions, Inc.
|
Buy |
5.86% |
-6.67% |
2025-01-08 |
AORT
Artivion, Inc.
|
Buy |
6.43% |
-1.82% |
2025-01-09 |
ARDX
Ardelyx, Inc.
|
Buy |
6.89% |
5.24% |
2025-01-09 |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
7.18% |
-4.27% |
2025-01-13 |
AXGN
AxoGen, Inc.
|
Buy |
8.27% |
-0.05% |
2025-01-14 |
INSM
Insmed Incorporated
|
Buy |
8.19% |
-0.93% |
2025-01-14 |
NUTX
Nutex Health Inc.
|
Buy |
8.28% |
0% |
2025-01-15 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
8.28% |
0% |
2025-01-15 |
TGTX
TG Therapeutics, Inc.
|
Sell |
-4.01% |
-6.21% |
2025-01-07 |
FATE
Fate Therapeutics, Inc.
|
Sell |
-2.68% |
28.57% |
2025-01-08 |
ORMP
Oramed Pharmaceuticals Inc.
|
Sell |
-3.71% |
0.84% |
2025-01-09 |
APLS
Apellis Pharmaceuticals, Inc.
|
Sell |
-3.84% |
-0.91% |
2025-01-13 |
VKTX
Viking Therapeutics, Inc.
|
Sell |
-3.29% |
13.69% |
2025-01-13 |
AVXL
Anavex Life Sciences Corp.
|
Sell |
-4.21% |
0.76% |
2025-01-14 |
EBS
Emergent BioSolutions Inc.
|
Sell |
-4.22% |
0.53% |
2025-01-14 |
GERN
Geron Corporation
|
Sell |
-4.03% |
0% |
2025-01-15 |
The percentage of cash held in the portfolio is:
59.97%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
NUTX |
Buy
All
|
-3.63% |
Assets Rebalanced
None
2025-01-14 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
5.8% |
-3.07% |
2025-01-07 |
BLUE
bluebird bio, Inc.
|
Buy |
5.12% |
-14.42% |
2025-01-07 |
MDRX
Allscripts Healthcare Solutions, Inc.
|
Buy |
6.07% |
-2.56% |
2025-01-08 |
AORT
Artivion, Inc.
|
Buy |
6.31% |
-2.94% |
2025-01-09 |
ARDX
Ardelyx, Inc.
|
Buy |
7.16% |
10.11% |
2025-01-09 |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
7.25% |
-2.56% |
2025-01-13 |
AXGN
AxoGen, Inc.
|
Buy |
8.21% |
0% |
2025-01-14 |
INSM
Insmed Incorporated
|
Buy |
8.21% |
0% |
2025-01-14 |
TGTX
TG Therapeutics, Inc.
|
Sell |
-3.71% |
1.18% |
2025-01-07 |
FATE
Fate Therapeutics, Inc.
|
Sell |
-2.75% |
26.29% |
2025-01-08 |
ORMP
Oramed Pharmaceuticals Inc.
|
Sell |
-3.69% |
0.84% |
2025-01-09 |
NUTX
Nutex Health Inc.
|
Sell |
-3.77% |
0.39% |
2025-01-13 |
APLS
Apellis Pharmaceuticals, Inc.
|
Sell |
-3.94% |
-4.19% |
2025-01-13 |
VKTX
Viking Therapeutics, Inc.
|
Sell |
-3.74% |
1.09% |
2025-01-13 |
AVXL
Anavex Life Sciences Corp.
|
Sell |
-4.21% |
0% |
2025-01-14 |
EBS
Emergent BioSolutions Inc.
|
Sell |
-4.21% |
0% |
2025-01-14 |
The percentage of cash held in the portfolio is:
75.87%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2025-01-13 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
5.84% |
-3.63% |
2025-01-07 |
BLUE
bluebird bio, Inc.
|
Buy |
5.17% |
-14.72% |
2025-01-07 |
MDRX
Allscripts Healthcare Solutions, Inc.
|
Buy |
6.15% |
-2.46% |
2025-01-08 |
AORT
Artivion, Inc.
|
Buy |
6.5% |
-1.16% |
2025-01-09 |
ARDX
Ardelyx, Inc.
|
Buy |
6.25% |
-5.06% |
2025-01-09 |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
7.54% |
0% |
2025-01-13 |
TGTX
TG Therapeutics, Inc.
|
Sell |
-3.91% |
-3.14% |
2025-01-07 |
FATE
Fate Therapeutics, Inc.
|
Sell |
-3.17% |
16% |
2025-01-08 |
ORMP
Oramed Pharmaceuticals Inc.
|
Sell |
-3.78% |
-0.42% |
2025-01-09 |
NUTX
Nutex Health Inc.
|
Sell |
-3.83% |
0% |
2025-01-13 |
APLS
Apellis Pharmaceuticals, Inc.
|
Sell |
-3.83% |
0% |
2025-01-13 |
VKTX
Viking Therapeutics, Inc.
|
Sell |
-3.83% |
0% |
2025-01-13 |
The percentage of cash held in the portfolio is:
84.9%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2025-01-09 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
6.06% |
0.36% |
2025-01-07 |
BLUE
bluebird bio, Inc.
|
Buy |
5.15% |
-14.72% |
2025-01-07 |
MDRX
Allscripts Healthcare Solutions, Inc.
|
Buy |
6.14% |
-2.46% |
2025-01-08 |
AORT
Artivion, Inc.
|
Buy |
6.56% |
0% |
2025-01-09 |
ARDX
Ardelyx, Inc.
|
Buy |
6.56% |
0% |
2025-01-09 |
TGTX
TG Therapeutics, Inc.
|
Sell |
-3.89% |
-2.75% |
2025-01-07 |
FATE
Fate Therapeutics, Inc.
|
Sell |
-3.59% |
4.57% |
2025-01-08 |
ORMP
Oramed Pharmaceuticals Inc.
|
Sell |
-3.75% |
0% |
2025-01-09 |
The percentage of cash held in the portfolio is:
80.75%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2025-01-08 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
5.97% |
-0.82% |
2025-01-07 |
BLUE
bluebird bio, Inc.
|
Buy |
5.47% |
-9.07% |
2025-01-07 |
MDRX
Allscripts Healthcare Solutions, Inc.
|
Buy |
6.27% |
0% |
2025-01-08 |
TGTX
TG Therapeutics, Inc.
|
Sell |
-3.77% |
0% |
2025-01-07 |
FATE
Fate Therapeutics, Inc.
|
Sell |
-3.75% |
0% |
2025-01-08 |
The percentage of cash held in the portfolio is:
89.8%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2025-01-07 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
5.99% |
0% |
2025-01-07 |
BLUE
bluebird bio, Inc.
|
Buy |
5.99% |
0% |
2025-01-07 |
TGTX
TG Therapeutics, Inc.
|
Sell |
-3.75% |
0% |
2025-01-07 |
The percentage of cash held in the portfolio is:
91.78%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-12-19 00:00:00
: Portfolio change date
No Asset in the portfolio
The percentage of cash held in the portfolio is:
100%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
CARA |
Buy
All
|
4.38% |
PCRX |
Sell
All
|
0.52% |
Assets Rebalanced
None
2024-12-18 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
PCRX
Pacira BioSciences, Inc.
|
Buy |
8.09% |
3.88% |
2024-12-05 |
CARA
Cara Therapeutics, Inc.
|
Sell |
-2.99% |
8.76% |
2024-12-05 |
The percentage of cash held in the portfolio is:
94.89%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
CUTR |
Buy
All
|
14.63% |
ATEC |
Buy
All
|
4.8% |
NKTR |
Buy
All
|
4.67% |
Assets Rebalanced
None
2024-12-17 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
PCRX
Pacira BioSciences, Inc.
|
Buy |
8.11% |
4.09% |
2024-12-05 |
CUTR
Cutera, Inc.
|
Sell |
-3.41% |
14.63% |
2024-12-04 |
ATEC
Alphatec Holdings, Inc.
|
Sell |
-3.79% |
5.3% |
2024-12-04 |
NKTR
Nektar Therapeutics
|
Sell |
-3.74% |
6.54% |
2024-12-04 |
CARA
Cara Therapeutics, Inc.
|
Sell |
-3.08% |
5.84% |
2024-12-05 |
The percentage of cash held in the portfolio is:
105.91%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
FATE |
Buy
All
|
32.43% |
Assets Rebalanced
None
2024-12-16 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
PCRX
Pacira BioSciences, Inc.
|
Buy |
8.11% |
4.03% |
2024-12-05 |
FATE
Fate Therapeutics, Inc.
|
Sell |
-2.28% |
38.18% |
2024-12-03 |
CUTR
Cutera, Inc.
|
Sell |
-3.51% |
12.2% |
2024-12-04 |
ATEC
Alphatec Holdings, Inc.
|
Sell |
-3.85% |
3.8% |
2024-12-04 |
NKTR
Nektar Therapeutics
|
Sell |
-3.78% |
5.61% |
2024-12-04 |
CARA
Cara Therapeutics, Inc.
|
Sell |
-3.13% |
4.38% |
2024-12-05 |
The percentage of cash held in the portfolio is:
108.44%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
IBRX |
Buy
All
|
43.06% |
Assets Rebalanced
None
2024-12-12 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
PCRX
Pacira BioSciences, Inc.
|
Buy |
8.35% |
6.5% |
2024-12-05 |
IBRX
ImmunityBio, Inc.
|
Sell |
-2.31% |
37.5% |
2024-12-02 |
FATE
Fate Therapeutics, Inc.
|
Sell |
-2.74% |
26.35% |
2024-12-03 |
CUTR
Cutera, Inc.
|
Sell |
-3.53% |
12.2% |
2024-12-04 |
ATEC
Alphatec Holdings, Inc.
|
Sell |
-3.9% |
3.1% |
2024-12-04 |
NKTR
Nektar Therapeutics
|
Sell |
-3.83% |
4.67% |
2024-12-04 |
CARA
Cara Therapeutics, Inc.
|
Sell |
-3.21% |
2.55% |
2024-12-05 |
The percentage of cash held in the portfolio is:
111.18%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
SEM |
Buy
All
|
3.29% |
ESPR |
Sell
All
|
-13.23% |
Assets Rebalanced
None